What Happens to Babies Exposed to Cannabis Before Birth

This review synthesizes the accumulating evidence on what happens when a developing fetus is exposed to cannabis—a question of increasing urgency as both cannabis use during pregnancy and THC potency rise simultaneously.

The pharmacological reality is concerning. THC crosses the placenta, disrupts the fetal endocannabinoid system that's critical for neurodevelopment, and accumulates in fetal tissues. For breastfeeding mothers, THC transfers into breast milk at approximately 2.5% of the maternal dose.

The clinical evidence has reached a critical mass. Multiple studies and meta-analyses now associate prenatal cannabis exposure with low birth weight, preterm birth, neonatal intensive care unit admission, and reduced Apgar scores. These aren't subtle statistical associations—they're clinically meaningful outcomes.

The neurodevelopmental data is perhaps most alarming. Longitudinal studies tracking exposed children over time have documented brain alterations affecting memory, attention, and executive function. These aren't just neonatal effects that resolve—they appear to be lasting changes in how the brain develops.

A crucial contextual factor: THC concentrations in cannabis products have risen dramatically, from roughly 5% to 30% over recent decades. A pregnant woman using cannabis today is exposing her fetus to far more THC than a woman using cannabis 20 years ago, yet much of the existing research was conducted with lower-potency products.

The ethical impossibility of randomized controlled trials in pregnant women means all evidence is observational, which limits causal conclusions. But the consistency and biological plausibility of the findings have strengthened the evidence base substantially.